Bausch + Lomb Co. (NYSE:BLCO) Receives $20.00 Average PT from Brokerages

Bausch + Lomb Co. (NYSE:BLCO) has received a consensus rating of “Hold” from the twelve research firms that are presently covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have given a hold recommendation and five have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $20.00.

BLCO has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and issued a $23.00 price objective on shares of Bausch + Lomb in a research note on Tuesday, February 18th. Royal Bank of Canada lowered their price target on Bausch + Lomb from $22.00 to $18.00 and set an “outperform” rating for the company in a report on Thursday, February 20th. Bank of America reduced their price objective on Bausch + Lomb from $18.00 to $17.00 and set an “underperform” rating on the stock in a research note on Thursday, February 20th. Wells Fargo & Company lowered their target price on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating for the company in a research note on Thursday, January 16th. Finally, Morgan Stanley lowered shares of Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price target on the stock. in a report on Monday, December 2nd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. raised its position in shares of Bausch + Lomb by 80.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 29,755 shares of the company’s stock worth $576,000 after acquiring an additional 13,302 shares during the last quarter. Verition Fund Management LLC acquired a new stake in Bausch + Lomb during the 3rd quarter valued at approximately $302,000. Cinctive Capital Management LP bought a new position in Bausch + Lomb during the 3rd quarter worth approximately $870,000. HighTower Advisors LLC lifted its position in shares of Bausch + Lomb by 14.7% in the 3rd quarter. HighTower Advisors LLC now owns 24,661 shares of the company’s stock worth $476,000 after purchasing an additional 3,164 shares during the period. Finally, Janus Henderson Group PLC bought a new stake in shares of Bausch + Lomb in the 3rd quarter valued at $957,000. 11.07% of the stock is owned by institutional investors and hedge funds.

Bausch + Lomb Price Performance

Bausch + Lomb stock opened at $14.98 on Friday. The stock’s fifty day moving average price is $16.30 and its two-hundred day moving average price is $18.09. The firm has a market cap of $5.28 billion, a PE ratio of -16.46, a price-to-earnings-growth ratio of 0.85 and a beta of 0.49. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.60 and a quick ratio of 1.01. Bausch + Lomb has a one year low of $13.16 and a one year high of $21.69.

Bausch + Lomb (NYSE:BLCO) last posted its quarterly earnings data on Wednesday, February 19th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.02. The business had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.26 billion. Bausch + Lomb had a negative net margin of 6.62% and a positive return on equity of 3.35%. Bausch + Lomb’s revenue was up 9.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.24 earnings per share. As a group, research analysts expect that Bausch + Lomb will post 0.74 EPS for the current fiscal year.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.